Subsequently, a series of small‐molecule TKIs targeting specific oncogenic drivers, including ALK, ROS1, KRAS, BRAF, MET, and NTRK, were developed and approved as the preferred treatments for advanced NSCLC.6 Here, ALK is linked to non-small cell lung carcinoma.